JP2001514651A5 - - Google Patents

Download PDF

Info

Publication number
JP2001514651A5
JP2001514651A5 JP1998539357A JP53935798A JP2001514651A5 JP 2001514651 A5 JP2001514651 A5 JP 2001514651A5 JP 1998539357 A JP1998539357 A JP 1998539357A JP 53935798 A JP53935798 A JP 53935798A JP 2001514651 A5 JP2001514651 A5 JP 2001514651A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998539357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001514651A (ja
Filing date
Publication date
Priority claimed from GBGB9704978.7A external-priority patent/GB9704978D0/en
Priority claimed from GBGB9719261.1A external-priority patent/GB9719261D0/en
Application filed filed Critical
Priority claimed from PCT/GB1998/000726 external-priority patent/WO1998040053A1/en
Publication of JP2001514651A publication Critical patent/JP2001514651A/ja
Publication of JP2001514651A5 publication Critical patent/JP2001514651A5/ja
Ceased legal-status Critical Current

Links

JP53935798A 1997-03-11 1998-03-11 R−およびs−エナンチオマーの別の部分を含む製剤 Ceased JP2001514651A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9704978.7A GB9704978D0 (en) 1997-03-11 1997-03-11 Dosage forms
GB9704978.7 1997-03-11
GB9719261.1 1997-09-10
GBGB9719261.1A GB9719261D0 (en) 1997-09-10 1997-09-10 Dosage forms
PCT/GB1998/000726 WO1998040053A1 (en) 1997-03-11 1998-03-11 Dosage forms comprising separate portions of r- and s-enantiomers
US09/038,873 US6056968A (en) 1997-03-11 1998-03-11 Pharmaceutical drug dosage forms providing different release rates

Publications (2)

Publication Number Publication Date
JP2001514651A JP2001514651A (ja) 2001-09-11
JP2001514651A5 true JP2001514651A5 (enExample) 2005-11-10

Family

ID=27268767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53935798A Ceased JP2001514651A (ja) 1997-03-11 1998-03-11 R−およびs−エナンチオマーの別の部分を含む製剤

Country Status (15)

Country Link
US (2) US6056968A (enExample)
EP (1) EP0969818B1 (enExample)
JP (1) JP2001514651A (enExample)
CN (1) CN1251987A (enExample)
AT (1) ATE275394T1 (enExample)
AU (1) AU741821B2 (enExample)
BR (1) BR9808325A (enExample)
CA (1) CA2285407C (enExample)
DE (1) DE69826113T2 (enExample)
ES (1) ES2227814T3 (enExample)
HU (1) HUP0000759A3 (enExample)
IL (1) IL131713A (enExample)
NO (1) NO994412L (enExample)
PL (1) PL335619A1 (enExample)
WO (1) WO1998040053A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
IL142778A0 (en) * 1998-12-02 2002-03-10 Darwin Discovery Ltd Therapeutic product and its use
WO2000043003A1 (en) * 1999-01-21 2000-07-27 Darwin Discovery Limited The therapeutic use of r-warfarin as anticoagulant
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
PE20010623A1 (es) * 1999-10-05 2001-07-07 Gruenenthal Chemie Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
WO2001034125A2 (en) * 1999-11-09 2001-05-17 Darwin Discovery Limited Therapeutic use and formulation of (-)-tramadol
DE10004926A1 (de) 2000-02-04 2001-08-09 Gruenenthal Gmbh Verfahren zur enzymatischen Racematspaltung von Aminomethyl-Aryl-Cyclohexanol-Derivaten
WO2001064202A2 (en) 2000-03-01 2001-09-07 Euro-Celtique S.A. Tramadol for the treatment of functional gastrointestinal disorders
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
EP1322303A1 (en) * 2000-10-03 2003-07-02 Penwest Pharmaceuticals Co. Delivery system for multi-pharmaceutical active materials at various release rates
CA2426811A1 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol
US6562871B1 (en) * 2000-11-06 2003-05-13 Boehringer Ingelheim Pharmaceuticals, Inc. Dry granulation of pharmaceutical formulation comprising mexiletine
DE10108122A1 (de) 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
IN191028B (enExample) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US6780891B2 (en) 2001-11-30 2004-08-24 Sepracor Inc. Tramadol analogs and uses thereof
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US20040151772A1 (en) * 2002-11-08 2004-08-05 Egalet A/S Controlled release carvedilol compositions
AU2003288608A1 (en) * 2002-12-20 2004-07-14 Ranbaxy Laboratories Limited Controlled release, multiple unit drug delivery systems
US20040220277A1 (en) * 2003-02-10 2004-11-04 Couch Richard A. Enantiomeric amphetamine compositions
WO2004103361A2 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited A pharmaceutical dosage form of citalopram
WO2004110411A2 (fr) * 2003-06-06 2004-12-23 Ethypharm Comprime orodispersible multicouche
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005051322A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
CA2580329C (en) 2004-09-13 2015-01-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
CA2581282A1 (en) * 2004-10-01 2006-04-13 Nippon Zoki Pharmaceutical Co., Ltd. Solid pharmaceutical preparation
US8795723B2 (en) 2005-09-09 2014-08-05 Angelini Pharma Inc. Sustained drug release compositions
EP1976488A4 (en) * 2006-01-12 2010-02-10 Wockhardt Ltd ALFUZOSIN PROLONGED RELEASE PREPARATIONS
ES2744495T3 (es) * 2006-03-30 2020-02-25 Nippon Zoki Pharmaceutical Co Preparación farmacéutica sólida
KR20130122023A (ko) 2007-02-12 2013-11-06 디엠아이 바이오사이언시스 인코포레이티드 트라마돌의 부작용을 감소시키는 방법
CA2677690C (en) * 2007-02-12 2012-05-15 James V. Winkler Treatment of comorbid premature ejaculation and erectile dysfunction
EP1977746B8 (en) 2007-04-02 2014-09-24 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818541A (en) * 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
US5145866A (en) * 1991-04-22 1992-09-08 Hoechst-Roussel Pharmaceuticals Incorporated Method of treating anxiety with the aid of r(+)-3-amino-1-hydroxy-pyrrolidin-2-one
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
DE4319438C1 (de) * 1993-06-11 1994-06-01 Gerd Dr Dr Geislinger Arzneimittel auf der Grundlage von Ketoprofen zur Bekämpfung von Schmerzen und/oder Entzündungen und/oder Fieber an Menschen und Tieren
GB9412689D0 (en) * 1994-06-23 1994-08-10 Chiroscience Ltd Cytotoxic agent and its use

Similar Documents

Publication Publication Date Title
JP2000509942A5 (enExample)
JP2000509912A5 (enExample)
JP2000510751A5 (enExample)
JP2000507042A5 (enExample)
JP2002503166A5 (enExample)
JP2002508116A5 (enExample)
JP2000507369A5 (enExample)
JP2000507433A5 (enExample)
JP2001501070A5 (enExample)
JP2000508866A5 (enExample)
JP2000510793A5 (enExample)
JP2000508022A5 (enExample)
JP2000508841A5 (enExample)
JP2001514651A5 (enExample)
JP2000508680A5 (enExample)
JP2000509804A5 (enExample)
JP2000509853A5 (enExample)
JP2000509755A5 (enExample)
JP2002511754A5 (enExample)
JP2000510969A5 (enExample)
JP2000510247A5 (enExample)
JP2000508836A5 (enExample)
JP2000508102A5 (enExample)
JP2000509818A5 (enExample)
JP2001500923A5 (enExample)